The Tuberculosis drugs in development market research report provides comprehensive information on the therapeutics under development for Tuberculosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Tuberculosis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Tuberculosis and features dormant and discontinued products.
GlobalData tracks 241 drugs in development for Tuberculosis by 174 companies/universities/institutes. The top development phase for Tuberculosis is preclinical with 99 drugs in that stage. The Tuberculosis pipeline has 137 drugs in development by companies and 104 by universities/ institutes. Some of the companies in the Tuberculosis pipeline products market are: Global Alliance for TB Drug Development, GSK and Foundation For Neglected Disease Research.
The key targets in the Tuberculosis pipeline products market include FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase, H+ Transporting Two Sector ATPase, and Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI.
The key mechanisms of action in the Tuberculosis pipeline product include FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase Inhibitor with seven drugs in Phase II. The Tuberculosis pipeline products include 11 routes of administration with the top ROA being Oral and 19 key molecule types in the Tuberculosis pipeline products market including Small Molecule, and Subunit Vaccine.
Tuberculosis overview
Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus; fatigue; shortness of breath; weight loss; and pain in the chest.
For a complete picture of Tuberculosis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
